Hypertension Journal

Register      Login

VOLUME 2 , ISSUE 1 ( January-March, 2016 ) > List of Articles

RESEARCH ARTICLE

Statins for All Patients with Hypertension—It is still not Prime Time!

Nagaraj Desai, Chilkunda Raviprakash Venkatesh

Keywords : HMG-CoA reductase inhibitors,Hypertension,Primary prevention,Statins

Citation Information : Desai N, Venkatesh CR. Statins for All Patients with Hypertension—It is still not Prime Time!. Hypertens J 2016; 2 (1):44-50.

DOI: 10.5005/jp-journals-10043-0029

Published Online: 00-03-2016

Copyright Statement:  Copyright © 2016; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

How to cite this article

Desai N, Venkatesh CR. Statins for All Patients with Hypertension—It is still not Prime Time! Hypertens J 2016;2(1):44-50.


PDF Share
  1. Non optimal lipids commonly present in young adults and coronary calcium later in life: the coronary artery risk development in young adults (CARDIA) study. Ann Intern Med 2010 Aug3;153(3):137-146.
  2. Statin therapy for primary prevention of cardiovascular disease. JAMA 2013 Dec11;310(22):2451-2452.
  3. Global and regional mortality from 235 causes of death for 20 age groups in 1990and 2010:a systematic analysis for the global burden of disease study 2010. Lancet 2012 Dec 15;380(9859): 2095-2128.
  4. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation 2014 Jan1;127(1): e6-e245.
  5. Cardiovascular disease in Europe: epidemiological update. Eur Heart J 2013 Oct;34(39):3028-3034.
  6. Prevalence, correlates, awareness, treatment, and control of hypertension in a middle-aged urban population in Kerala. Ind Heart J 2003 May-Jun;55(3):245-251.
  7. Relationships between chronic use of statin therapy, presentation of acute coronary syndromes and one-year mortality after an incident acute coronary event. Int J Cardiol 2013 Feb10;163(1):102-104.
  8. Trends in utilization of lipid-and blood pressure-lowering agents and goal attainment among the US diabetic population, 1999—2008. Cardiovasc Diabetol 2011 Apr 17;10:31.
  9. Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001–2010. BMC Nephrol 2013 Jun27;14:132.
  10. Time trends in population cholesterol levels 1986–2004:influence of lipid-lowering drugs, obesity, smoking and educational level. The northern Sweden MONICA study. J Intern Med 2006 Dec;260(6):551-559.
  11. Trends in plasma lipids, lipoproteins and dyslipidaemias in French adults, 1996–2007. Arch Cardiovasc Dis 2009 Apr;102(4):293-301.
  12. Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: insights from the MONALISA study. Arch Cardiovasc Dis 2013 Feb;106(2):93-102.
  13. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011 Jul;32(14):1769-1818.
  14. ALLHAT Collaborative Research Group Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J Clin Hypertens (Greenwich) 2013 Aug;15(8):542-554.
  15. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996 Apr;9(4 Pt 1):342-360.
  16. First United Kingdom heart and renal protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 2005 Mar;45(3):473-484.
  17. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002 Dec 18;288(23):2998-3007.
  18. Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). Am Heart J 2009 Dec;158(6):948-955.
  19. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. Eur Heart J 2011 Oct;32(20):2525-2532.
  20. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011 Jul;32(14):1769-1818.
  21. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol 2012 01;2(Dec):25-60.
  22. Evidence based management of hypertension: using cardiovascular risk profiles to individualise hypertensive treatment. BMJ 2001 May 12;322(7295): 1164-1166.
  23. Safety profiles for the HMG-Co A reductase inhibitors: treatment and trust. Drugs 2001;61(2):197-206.
  24. Safety of HMG-Co A reductase inhibitors: focus on atorvastatin. Cardiovasc Drugs Ther 2001;15(3):211-218.
  25. Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem 2007 Jun;40(9-10):575-584.
  26. Regulation of the mevalonate pathway. Nature 1990 Feb 1;343(6257):425-430.
  27. Statins as immunomodulatory agents. Circulation 2004 Jun 1;109(21 Suppl 1):II15-II17.
  28. Effects of inhibition of cholesterol synthesis by simvastatin on the production of adrenocortical steroid hormones and ACTH. Clin Endocrinol (Oxf) 1989 Dec;31(6):679-689.
  29. Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial. Psychoneuroendocrinology 2003 Feb;28(2):181-194.
  30. Statins: multiple mechanisms of action in the ischemic brain. Neuroscientist 2007 Jun;13(3):208-213.
  31. Statin treatment alters serum n-3 and n-6 fatty acids in hypercholester-olemic patients. Prostaglandins Leukot Essent Fatty Acids 2004 Oct;71(4):263-269.
  32. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol 2004 Jun;61(6):889-892.
  33. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008;8(6):373-418.
  34. Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias. QJM 1999 Jul;92(7):387-394.
  35. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006 Aug;34(2):153-162.
  36. Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol Drug Saf 2007 Feb;16(2):132-143.
  37. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 2003 Feb 11;107(5):757-761.
  38. Pleiotropic effects of statins in atherosclerosis: role on endothelial function, inflammation and immunomodulation. Arch Mal Coeur Vaiss 2005 Jun;98(6):661-666.
  39. Scripps Mercy Clinical Research Center. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002 Oct 1;137(7): 581-585.
  40. Statin-associated myopathy with normal creatine kinase levels. Case report from a Norwegian family. APMIS 2005 Sep;113(9):635-637.
  41. Mild to moderate muscular symptoms with high dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther 2005 Dec;19(6):403-414.
  42. Rhabdomyolysis in patients with preexisting myopathy, treated with antilipemic agents. Presse Med 1997 Dec 6;26(38):1855-1858.
  43. Risk for fatal statin-induced rhabdomyolysis as a consequence of misinterpretation of ‘evidence-based medicine’. J Intern Med 2005 Mar;257(3):313-314.
  44. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006 May;119(5):400-409.
  45. Statin safety: an assessment using an administrative claims database. Am J Cardiol 2006 Apr 17;97(8A):61C-68C.
  46. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004 Dec 1;292(21): 2585-2590.
  47. Cerivastatin and gemfibrozil-induced cardiac rhabdomyolysis. Am J Forensic Med Pathol 2002 Sep;23(3):305-306.
  48. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 2007 Feb;29(2):253-260.
  49. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006 Dec;80(6):565-581.
  50. Mitochondrial bioenergetics in aging. Biochim Biophys Acta 2000 Aug 15;1459(2-3):397–404.
  51. The selfish brain: competition for energy resources. Prog Brain Res 2006;153:129-140.
  52. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004 May;24(5):584-591.
  53. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials. Am J Cardiol 2008 Dec 15;102(12):1654-1662.
  54. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: 2-year efficacy and safety follow-up. Am J Cardiol 1994 Oct 1;74(7):667-673.
  55. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011 Jul;217(1):3-46.
  56. An assessment of statin safety by hepatologists. Am J Cardiol 2006 Apr 17;97(8A):77C-81C.
  57. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006 Apr 17;97(8A):89C-94C.
  58. FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother 2012 Aug;10(4):264-271.
  59. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005 Feb;329(2):62-65.
  60. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004 May;126(5):1287-1292.
  61. Jr, Considerations for safe use of statins: liver enzyme abnormalities and muscle toxicity. Am Fam Physician 2011 Mar 15;83(6):711-716.
  62. The role of mitochondrial oxidative stress in aging. Free Radic Biol Med 2003 Jul 1;35(1):1-8.
  63. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. Drug Saf 2007;30(8):669-675.
  64. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008 Nov 20;359(21):2195-2207.
  65. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010 Feb 27;375(9716):735-742.
  66. Effects of rosuvastatin and atorvastatin on glycemic control in type 2 diabetes: the Corall Study. Diabet Med 2012 May;29(5):628-631.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.